Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CELSA, Ciro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.891
AS - Asia 3.034
EU - Europa 3.030
Continente sconosciuto - Info sul continente non disponibili 651
SA - Sud America 526
AF - Africa 81
OC - Oceania 9
Totale 12.222
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.700
RU - Federazione Russa 1.086
SG - Singapore 1.056
IT - Italia 782
CN - Cina 599
BR - Brasile 399
BD - Bangladesh 333
HK - Hong Kong 320
VN - Vietnam 308
DE - Germania 265
PL - Polonia 221
FR - Francia 158
FI - Finlandia 130
GB - Regno Unito 112
CA - Canada 106
JP - Giappone 103
IN - India 65
AT - Austria 44
AR - Argentina 42
SE - Svezia 38
TR - Turchia 36
ES - Italia 35
IE - Irlanda 34
MX - Messico 31
KR - Corea 30
NL - Olanda 30
IQ - Iraq 29
EC - Ecuador 26
VE - Venezuela 20
ZA - Sudafrica 20
CI - Costa d'Avorio 16
MY - Malesia 15
UZ - Uzbekistan 15
CR - Costa Rica 14
PK - Pakistan 14
PY - Paraguay 14
RO - Romania 14
SA - Arabia Saudita 14
BE - Belgio 12
ID - Indonesia 12
JM - Giamaica 12
UA - Ucraina 12
CO - Colombia 11
EG - Egitto 11
LT - Lituania 11
PH - Filippine 11
AE - Emirati Arabi Uniti 9
MA - Marocco 9
AU - Australia 8
DZ - Algeria 8
CH - Svizzera 7
CL - Cile 7
JO - Giordania 7
KZ - Kazakistan 7
IL - Israele 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
GE - Georgia 5
HN - Honduras 5
NI - Nicaragua 5
NP - Nepal 5
TH - Thailandia 5
BS - Bahamas 4
CZ - Repubblica Ceca 4
GT - Guatemala 4
KE - Kenya 4
OM - Oman 4
PS - Palestinian Territory 4
RS - Serbia 4
TW - Taiwan 4
HR - Croazia 3
HU - Ungheria 3
NO - Norvegia 3
PT - Portogallo 3
UY - Uruguay 3
BG - Bulgaria 2
EE - Estonia 2
GP - Guadalupe 2
GR - Grecia 2
GY - Guiana 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
PE - Perù 2
QA - Qatar 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
BY - Bielorussia 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GL - Groenlandia 1
IR - Iran 1
KG - Kirghizistan 1
MG - Madagascar 1
Totale 11.559
Salva come PNG Salva come JPEG
Città #
Singapore 700
Ashburn 696
San Jose 581
Hong Kong 299
Chandler 277
Fairfield 212
Zgierz 192
Council Bluffs 171
Moscow 171
New York 170
Palermo 156
Los Angeles 142
Ho Chi Minh City 108
Beijing 107
Lauterbourg 97
Tokyo 95
Santa Clara 90
Houston 86
Hefei 84
Woodbridge 84
Rome 83
Helsinki 81
Seattle 72
Ann Arbor 68
Wilmington 68
Hanoi 67
The Dalles 67
Dallas 64
Altamura 63
Boardman 62
Medford 58
Buffalo 55
Milan 55
Cambridge 46
Frankfurt am Main 44
Lappeenranta 43
Orem 42
Lawrence 36
Nuremberg 36
Princeton 36
Dublin 34
São Paulo 33
Toronto 33
London 31
Chicago 29
Ludwigshafen am Rhein 28
Bremen 27
Montreal 27
Des Moines 26
Warsaw 25
Vienna 22
Brooklyn 21
Denver 21
San Diego 21
Atlanta 18
Poplar 18
Chennai 17
Da Nang 17
Phoenix 17
Abidjan 16
Florence 16
Washington 16
Bologna 15
Columbus 15
Johannesburg 14
Naples 14
Redondo Beach 14
San Francisco 14
Tashkent 14
Ankara 13
Brasília 13
Haiphong 13
Stockholm 13
West Jordan 12
Amsterdam 11
Biên Hòa 11
Quito 11
Turin 11
Belo Horizonte 10
Dhaka 10
Guangzhou 10
Rio de Janeiro 10
San José 10
Baghdad 9
Central 9
Hải Dương 9
Mexico City 9
Paris 9
Porto Alegre 9
Salt Lake City 9
Brussels 8
Cordova 8
Falkenstein 8
Gangbuk-gu 8
Istanbul 8
Kingston 8
Krefeld 8
Munich 8
Pune 8
Tianjin 8
Totale 6.578
Salva come PNG Salva come JPEG
Nome #
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 311
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 270
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 257
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 210
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 208
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 208
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 202
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 199
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 196
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 190
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 183
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 179
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 174
Systemic therapies for hepatocellular carcinoma: The present and the future 173
Biochemical biomarkers of NAFLD/NASH 168
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 166
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 162
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 162
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 160
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 160
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 159
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 157
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 155
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 154
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 154
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 148
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 146
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 144
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 140
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 139
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 135
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis 135
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 134
Biliary complications after liver transplantation: current perspectives and future strategies 132
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 132
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 129
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 129
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 128
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 128
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 128
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis 122
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 121
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 120
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death 119
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 116
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 116
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 112
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 112
Reply 112
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 110
Reply 110
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study 110
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 109
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 109
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 107
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 107
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 107
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 107
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 105
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 104
The Application of Large Language Models in Gastroenterology: A Review of the Literature 103
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 103
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 102
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma 99
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 94
Hepatocellular carcinoma in people living with HIV 93
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 93
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 91
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 91
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 90
Identification of clinical phenotypes and related survival in patients with large hccs 90
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 89
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma 85
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 84
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 84
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 83
Patients’ radiation exposure during TIPS creation in a high-volume referral hospital 82
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice 80
The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives 80
354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab 75
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT) 74
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 74
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 73
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 72
The price and value of therapeutic synergy in liver cancer 72
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis 70
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 69
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 63
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 62
Expert opinion vs. meta-analysis: To be or not to be? 61
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 58
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 57
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 56
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 54
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events 54
Reply to: “irLI or not irLI: That is the question” 52
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 51
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 51
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 50
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 50
Totale 11.993
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.490
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.490
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022448 0 0 16 17 5 14 10 158 70 32 32 94
2022/2023923 60 165 8 112 82 103 89 73 159 10 35 27
2023/2024550 24 54 36 43 19 153 59 17 17 29 32 67
2024/20251.768 35 125 217 131 31 140 146 82 96 193 229 343
2025/20266.950 417 165 393 679 611 991 858 850 561 461 503 461
2026/2027817 316 213 288 0 0 0 0 0 0 0 0 0
Totale 12.222